Welcome to our dedicated page for Biolargo SEC filings (Ticker: BLGO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
BioLargo, Inc. filings document an operating company with cleantech, environmental engineering and life sciences subsidiaries, including disclosures tied to product and service revenue, partially owned subsidiaries, debt obligations and common stock. Registration statements and related exhibits describe common stock, capital structure, resale registration rights and equity financing arrangements.
BioLargo's Form 8-K filings record Regulation FD materials, investor presentation exhibits, annual operating-result releases, shareholder town hall transcripts, material definitive agreements and officer compensation converted into common stock. The filings also provide formal disclosure around governance, liquidity, subsidiary activity and risk factors associated with commercializing water treatment, medical technology, engineering services and energy-storage businesses.
BioLargo, Inc. reported Q1 2026 revenue of $1.115M, down sharply from $3.269M a year earlier, as product revenue fell from $2.803M to $577K. Service revenue rose modestly to $538K.
The company posted a net loss of $3.405M versus $1.921M in Q1 2025, driven by lower gross profit, higher operating expenses and increased interest and finance costs. Operating loss widened to $3.204M.
At March 31, 2026, BioLargo had cash and equivalents of $4.122M, current liabilities of $4.932M, and working capital of $513K, but total stockholders’ equity turned to a deficit of $187K. Management states that current-year gross profits will not fund operations and that these factors “raise substantial doubt” about the company’s ability to continue as a going concern without increased revenues and/or additional financing.
BioLargo, Inc. furnished a shareholder town hall transcript and investor summary describing progress and challenges across its five operating subsidiaries, without providing new formal financial results. CEO Dennis Calvert outlined strategic milestones, capital structure, and commercialization plans.
He said BioLargo’s market cap is about $50 million with roughly 320 million shares outstanding, and estimated subsidiary Clyra Medical at roughly $100 million, of which BioLargo owns 48% plus a 6% gross sales royalty. Recent milestones cited include a first municipal PFAS-removal installation in Lake Stockholm, New Jersey, a $1.2 million mineral-extraction engineering contract, new Clyra distribution deals including Al Hikma in MENA, and a memorandum of understanding with global water firm Aquatech for PFAS projects.
Calvert emphasized capital efficiency, stating about $50 million of invested capital has built five subsidiaries, two already commercial. He discussed the loss of Pooph-licensed odor-control revenue, ongoing litigation to protect intellectual property, and efforts to reposition that asset. He also highlighted the Cellinity sodium-based battery venture, describing long-life, non-degrading storage as a national-scale opportunity, and reiterated his view that the stock is undervalued as the company enters what he called a harvesting phase.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.
BioLargo, Inc. filed a current report announcing that CEO Dennis P. Calvert will participate in a shareholder town hall meeting on May 5, 2026 at 1:00 PM Pacific Time, hosted on the BioLargo Shareholder Community Discord channel.
The town hall will feature a brief company update followed by a Q&A session with shareholders. The meeting will be recorded and a transcript will be filed on Form 8‑K prior to the market open the next day. The company also includes standard forward-looking statement and Safe Harbor language referencing risks described in its most recent SEC filings.
BioLargo, Inc. files an amendment to its 2025 annual report to add the Part III disclosures it had planned to provide via a proxy statement. The amendment leaves all previously reported financial statements unchanged.
The filing details board composition, committee membership and governance practices, noting four independent directors and combined CEO/Chairman roles. It describes executive employment agreements, with base salaries of $288,603 for both the CEO and Chief Science Officer and option-based compensation for the CFO and other executives.
BioLargo reports that directors are paid quarterly retainers entirely in stock options instead of cash, and that all Section 16 reports were timely except for one option grant to the CFO. The filing shows insiders collectively owning 19.3% of common stock as of April 30, 2026, outlines related‑party investments by the CEO in subsidiary Clyra Medical notes guaranteed by BioLargo, and discloses 2025 audit fees of $117,000 plus $9,000 in audit‑related services.
BioLargo, Inc. registers 31,730,651 shares of common stock for resale by selling stockholders; these shares are issuable upon exercise of warrants issued between April 16, 2021 and January 6, 2026. The company is not selling any shares here and will receive no proceeds from secondary sales; however, it may receive up to $8,416,462 if the warrants are exercised in full at a weighted average exercise price of $0.265 per share. Shares outstanding were 320,474,620 as of the prospectus date; assuming full exercise the post-issuance total would be 352,205,271 shares. Exercise prices range from $0.19 to $0.33, and certain warrants may be callable if the registration is effective and the market price meets the stated threshold.
BioLargo, Inc. registers 30,000,000 shares of common stock for resale by a selling stockholder under a registration statement filed pursuant to Rule 424(b)(4). The shares are reserved for issuance to Clearthink Capital Partners under a March 20, 2026 Purchase Agreement and related Registration Rights Agreement.
The Purchase Agreement contemplates up to $10,000,000 of purchases by Clearthink at a price equal to the average of the two lowest daily closing prices during the eight trading days preceding each purchase; the company will not receive proceeds from resales by Clearthink under this prospectus, though it may receive proceeds up to the $10,000,000 Commitment Amount if it directs sales to Clearthink consistent with the agreement. The Purchase Agreement contains a 9.99% Beneficial Ownership Cap and other customary terms; timing and amounts of any sales are within the parties' contractual mechanics.
BioLargo, Inc. is registering up to 31,730,651 shares of common stock for resale by existing warrant holders. The shares will be issued if investors exercise warrants that were sold between April 2021 and January 2026 at a weighted average price of $0.265 per share.
BioLargo will not sell any shares in this offering and will receive no proceeds from stockholder resales, but could receive up to $8.42 million in gross proceeds if all warrants are exercised. As of the prospectus date, the company had 320,474,620 shares outstanding, which would increase to 352,205,271 shares if all registered warrant shares are issued.
The company focuses on cleantech solutions including PFAS water treatment, industrial odor and VOC control, and a liquid-sodium battery platform. It reports recurring losses, substantial cash needs, a going-concern warning, heavy reliance on external financing, and material litigation tied to a former major private‑label odor-control customer.
BioLargo, Inc. filed an S-1 registering up to 30,000,000 shares of common stock for resale by Clearthink Capital Partners under an equity purchase agreement. BioLargo may sell shares to Clearthink over time and receive up to $10,000,000 in gross proceeds, while Clearthink resells the shares to the public.
The company had 320,474,620 shares outstanding as of the prospectus date, which would rise to 350,474,620 shares if all 30,000,000 shares are issued. The agreement includes a 9.99% beneficial ownership cap, and Clearthink is deemed an underwriter. BioLargo highlights significant risks, including ongoing Pooph litigation, a $15.2 million net loss in 2025, substantial cash use, going-concern doubts, reliance on external financings, and thin, penny-stock trading on the OTCQX Best Market.